GS
RVMD icon

GTS Securities’s Revolution Medicines RVMD Stock Holding History

GTS Securities’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,100
Closed -$418K – 4359
2023
Q3 		$418K Buy
+15,100
New +$448K ﹤0.01% 2792

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

GTS Securities's RVMD Position: Q2 2026 in Review

GTS Securities opened a new position in Revolution Medicines (RVMD) in Q2 2026: 1,151 shares worth $216K. The stake represents ﹤0.01% of the portfolio and ranks #1170 among its holdings.

694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • GTS Securities held 1,151 shares of Revolution Medicines worth $216K as of Q2 2026.
  • Revolution Medicines was a new GTS Securities position in Q2 2026.
  • Revolution Medicines made up ﹤0.01% of GTS Securities's portfolio in Q2 2026, its #1170 holding.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.